No cure for …..
One of my favorite quotes of all time comes from that famous English statesmen Sir Winston Churchill who was told he was overserved to which he responded – “I shall be sober in the morning, and you will still be disgustingly ugly.” I thought about this quote because Momma Kliff who also gets quoted quite frequently always said there is no cure for stupid. Even worse stupid has no capacity to learn. Reports...
Who will it be?
It seems like a matter of time before Tandem is acquired. The stock is sinking into the abyss, the Board seems content to do nothing and they are sitting on a boatload of cash. As we have noted before this is not like the last time the company was on the verge of collapse. Thankfully today besides sitting on over $500 million in cash they have an installed base of...
Let the games begin.
The US Food and Drug Administration (FDA) has announced the clearance of the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people aged 6 years or older with type 1 diabetes. Now it’s time for the games to begin. Here’s our take on how this might play out. 1. Insulet has the least to worry about here – the Omnipod 5 will continue to gain new users. 2. Medtronic...
Strange things going on, well maybe not.
We’ve paying close attention to the insulin pump space as we see the market at a critical juncture. Medtronic just launched the 780, Tandem’s shares are sinking like a stone, Beta Bionics is about to get FDA approval and Insulet continues to sit firmly upon the Iron Throne. Yet what’s more interesting is how each company is handling their various position. Let’s start with Medtronic. Although it’s early here in the...
How does it end?
In a space that’s growing like an uncontrolled weed it speaks volumes when a company in this space is sinking like a stone in a pond. Dexcom and Abbott own the CGM space have nothing but open field running ahead of them and little if any real competition. Medtronic plays in the CGM sandbox but only to the extent that their sensors are bound to their insulin delivery systems. They...
Diving into the wrong pool
As you can probably guess Momma Kliff didn’t have too much time for nonsense. Raising four rambunctious boys didn’t allow for nonsense. This is why I got a great laugh reading the transcript for yesterday’s Embecta earnings call. Embecta is GREAT at making sharp objects that stick people. However not content to be the best in one category they are foolishly developing a Type 2 patch pump. I will say this...
What now?
Come Sunday we celebrate Mother’s Day, and the most famous diabetes mom is of course Momma Kliff. Right now, not sure what mom is thinking about Tandem whose shares are trading at new lows these days. Knowing mom as we do, we’re pretty sure she’d say they are getting what they deserve. That thanks to poor decisions made while the company was rolling have come back to haunt them. What...